Preeclampsia is a placentally induced hypertensive disorder of pregnancy that is associated with substantial morbidity and mortality to mothers and fetuses. Clinical manifestations of preterm preeclampsia result from excess circulating soluble vascular endothelial growth factor receptor FLT1 (sFLT1 or sVEGFR1) of placental origin. Here we identify short interfering RNAs (siRNAs) that selectively silence the three sFLT1 mRNA isoforms primarily responsible for placental overexpression of sFLT1 without reducing levels of full-length FLT1 mRNA. Full chemical stabilization in the context of hydrophobic modifications enabled productive siRNA accumulation in the placenta (up to 7% of injected dose) and reduced circulating sFLT1 in pregnant mice (up to 50%). In a baboon preeclampsia model, a single dose of siRNAs suppressed sFLT1 overexpression and clinical signs of preeclampsia. Our results demonstrate RNAi-based extrahepatic modulation of gene expression with nonformulated siRNAs in nonhuman primates and establish a path toward a new treatment paradigm for patients with preterm preeclampsia.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Stevens, W. et al. Short-term costs of preeclampsia to the United States health care system. Am. J. Obstet. Gynecol. 217, 237–248.e216 (2017).
Maynard, S.E. et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Invest. 111, 649–658 (2003).
Levine, R.J. et al. Circulating angiogenic factors and the risk of preeclampsia. N. Engl. J. Med. 350, 672–683 (2004).
Heydarian, M. et al. Novel splice variants of sFlt1 are upregulated in preeclampsia. Placenta 30, 250–255 (2009).
Young, B.C., Levine, R.J. & Karumanchi, S.A. Pathogenesis of preeclampsia. Annu. Rev. Pathol. 5, 173–192 (2010).
Aubuchon, M., Schulz, L.C. & Schust, D.J. Preeclampsia: animal models for a human cure. Proc. Natl. Acad. Sci. USA 108, 1197–1198 (2011).
Chaiworapongsa, T. et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Am. J. Obstet. Gynecol. 190, 1541–1547; discussion 1547–1550 (2004).
Lu, F. et al. The effect of over-expression of sFlt-1 on blood pressure and the occurrence of other manifestations of preeclampsia in unrestrained conscious pregnant mice. Am. J. Obstet. Gynecol. 196, 396 e391–397; discussion 396 e397 (2007).
Ahmad, S. & Ahmed, A. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ. Res. 95, 884–891 (2004).
Redman, C.W. & Sargent, I.L. Latest advances in understanding preeclampsia. Science 308, 1592–1594 (2005).
Vorlová, S. et al. Induction of antagonistic soluble decoy receptor tyrosine kinases by intronic polyA activation. Mol. Cell 43, 927–939 (2011).
Kendall, R.L. & Thomas, K.A. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc. Natl. Acad. Sci. USA 90, 10705–10709 (1993).
Bujold, E. et al. Evidence supporting that the excess of the sVEGFR-1 concentration in maternal plasma in preeclampsia has a uterine origin. J. Matern. Fetal Neonatal Med. 18, 9–16 (2005).
Zeisler, H. et al. Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia. N. Engl. J. Med. 374, 13–22 (2016).
Sunderji, S. et al. Automated assays for sVEGF R1 and PlGF as an aid in the diagnosis of preterm preeclampsia: a prospective clinical study. Am. J. Obstet. Gynecol. 202, 40 e41–47 (2010).
Rana, S. et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 125, 911–919 (2012).
Chaiworapongsa, T. et al. Plasma concentrations of angiogenic/anti-angiogenic factors have prognostic value in women presenting with suspected preeclampsia to the obstetrical triage area: a prospective study. J. Matern. Fetal Neonatal Med. 27, 132–144 (2014).
Thadhani, R. et al. Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation 124, 940–950 (2011).
Thadhani, R. et al. Removal of soluble fms-like tyrosine kinase-1 by dextran sulfate apheresis in preeclampsia. J. Am. Soc. Nephrol. 27, 903–913 (2016).
Khvorova, A. & Watts, J.K. The chemical evolution of oligonucleotide therapies of clinical utility. Nat. Biotechnol. 35, 238–248 (2017).
Fitzgerald, K. et al. A highly durable RNAi therapeutic inhibitor of PCSK9. N. Engl. J. Med. 376, 41–51 (2017).
Khvorova, A. Oligonucleotide therapeutics – a new class of cholesterol-lowering drugs. N. Engl. J. Med. 376, 4–7 (2017).
Haraszti, R.A. et al. 5′-Vinylphosphonate improves tissue accumulation and efficacy of conjugated siRNAs in vivo. Nucleic Acids Res. 45, 7581–7592 (2017).
Soutschek, J. et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432, 173–178 (2004).
Byrne, M. et al. Novel hydrophobically modified asymmetric RNAi compounds (sd-rxRNA) demonstrate robust efficacy in the eye. J. Ocul. Pharmacol. Ther. 29, 855–864 (2013).
Khan, T. et al. Silencing myostatin using cholesterol-conjugated siRNAs induces muscle growth. Mol. Ther. Nucleic Acids 5, e342 (2016).
Hassler, M.R. et al. Comparison of partially and fully chemically-modified siRNA in conjugate-mediated delivery in vivo. Nucleic Acids Res. 46, 2185–2196 (2018).
Ashar-Patel, A. et al. FLT1 and transcriptome-wide polyadenylation site (PAS) analysis in preeclampsia. Sci. Rep. 7, 12139 (2017).
Palmer, K.R. et al. Placental-specific sFLT-1 e15a protein is increased in preeclampsia, antagonizes vascular endothelial growth factor signaling, and has antiangiogenic activity. Hypertension 66, 1251–1259 (2015).
Souders, C.A. et al. Circulating levels of sFlt1 splice variants as predictive markers for the development of preeclampsia. Int. J. Mol. Sci. 16, 12436–12453 (2015).
Birmingham, A. et al. A protocol for designing siRNAs with high functionality and specificity. Nat. Protoc. 2, 2068–2078 (2007).
Anderson, E.M. et al. Experimental validation of the importance of seed complement frequency to siRNA specificity. RNA 14, 853–861 (2008).
Khvorova, A., Reynolds, A. & Jayasena, S.D. Functional siRNAs and miRNAs exhibit strand bias. Cell 115, 209–216 (2003).
Schwarz, D.S. et al. Asymmetry in the assembly of the RNAi enzyme complex. Cell 115, 199–208 (2003).
Alterman, J.F. et al. Hydrophobically modified siRNAs silence huntingtin mRNA in primary neurons and mouse brain. Mol. Ther. Nucleic Acids 4, e266 (2015).
Godinho, B.M.D.C. et al. Pharmacokinetic profiling of conjugated therapeutic oligonucleotides: a high-throughput method based upon serial blood microsampling coupled to peptide nucleic acid hybridization assay. Nucleic Acid Ther. 27, 323–334 (2017).
Ly, S. et al. Visualization of self-delivering hydrophobically modified siRNA cellular internalization. Nucleic Acids Res. 45, 15–25 (2017).
Wang, S. et al. Cellular uptake mediated by epidermal growth factor receptor facilitates the intracellular activity of phosphorothioate-modified antisense oligonucleotides. Nucleic Acids Res. 46, 3579–3594 (2018).
Allerson, C.R. et al. Fully 2′-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA. J. Med. Chem. 48, 901–904 (2005).
Sela, S. et al. A novel human-specific soluble vascular endothelial growth factor receptor 1: cell-type-specific splicing and implications to vascular endothelial growth factor homeostasis and preeclampsia. Circ. Res. 102, 1566–1574 (2008).
Holme, A.M., Roland, M.C., Henriksen, T. & Michelsen, T.M. In vivo uteroplacental release of placental growth factor and soluble Fms-like tyrosine kinase-1 in normal and preeclamptic pregnancies. Am. J. Obstet. Gynecol. 215, 782 e781–782 e789 (2016).
Rajakumar, A. et al. Transcriptionally active syncytial aggregates in the maternal circulation may contribute to circulating soluble fms-like tyrosine kinase 1 in preeclampsia. Hypertension 59, 256–264 (2012).
Makris, A. et al. Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1. Kidney Int. 71, 977–984 (2007).
Amadio, M., Govoni, S. & Pascale, A. Targeting VEGF in eye neovascularization: what's new?: a comprehensive review on current therapies and oligonucleotide-based interventions under development. Pharmacol. Res. 103, 253–269 (2016).
Ambati, B.K. et al. Corneal avascularity is due to soluble VEGF receptor-1. Nature 443, 993–997 (2006).
Lertkiatmongkol, P., Liao, D., Mei, H., Hu, Y. & Newman, P.J. Endothelial functions of platelet/endothelial cell adhesion molecule-1 (CD31). Curr. Opin. Hematol. 23, 253–259 (2016).
Karumanchi, S.A. Angiogenic factors in preeclampsia: from diagnosis to therapy. Hypertension 67, 1072–1079 (2016).
Bergmann, A. et al. Reduction of circulating soluble Flt-1 alleviates preeclampsia-like symptoms in a mouse model. J. Cell. Mol. Med. 14 6B, 1857–1867 (2010).
Spradley, F.T. et al. Placental growth factor administration abolishes placental ischemia-induced hypertension. Hypertension 67, 740–747 (2016).
Makris, A. et al. Placental growth factor reduces blood pressure in a uteroplacental ischemia model of preeclampsia in nonhuman primates. Hypertension 67, 1263–1272 (2016).
Yu, D. et al. Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression. Cell 150, 895–908 (2012).
Nair, J.K. et al. Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc-siRNA conjugates. Nucleic Acids Res. 45, 10969–10977 (2017).
Pasi, K.J. et al. Targeting of antithrombin in hemophilia A or B with RNAi therapy. N. Engl. J. Med. 377, 819–828 (2017).
Matsuda, S. et al. siRNA conjugates carrying sequentially assembled trivalent N-acetylgalactosamine linked through nucleosides elicit robust gene silencing in vivo in hepatocytes. ACS Chem. Biol. 10, 1181–1187 (2015).
Nair, J.K. et al. Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J. Am. Chem. Soc. 136, 16958–16961 (2014).
Wolfrum, C. et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat. Biotechnol. 25, 1149–1157 (2007).
Krützfeldt, J. et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 438, 685–689 (2005).
Baerlocher, G.M., Burington, B. & Snyder, D.S. Telomerase inhibitor imetelstat in essential thrombocythemia and myelofibrosis. N. Engl. J. Med. 373, 2580 (2015).
Yu, J., Jia, J., Guo, X., Chen, R. & Feng, L. Modulating circulating sFlt1 in an animal model of preeclampsia using PAMAM nanoparticles for siRNA delivery. Placenta 58, 1–8 (2017).
Khankin, E.V., Mandala, M., Colton, I., Karumanchi, S.A. & Osol, G. Hemodynamic, vascular, and reproductive impact of FMS-like tyrosine kinase 1 (FLT1) blockade on the uteroplacental circulation during normal mouse pregnancy. Biol. Reprod. 86, 57 (2012).
Yu, R.Z. et al. Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100. Drug Metab. Dispos. 35, 460–468 (2007).
Geary, R.S., Norris, D., Yu, R. & Bennett, C.F. Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv. Drug Deliv. Rev. 87, 46–51 (2015).
Savage, V.M. et al. Scaling of number, size, and metabolic rate of cells with body size in mammals. Proc. Natl. Acad. Sci. USA 104, 4718–4723 (2007).
Fan, X. et al. Endometrial VEGF induces placental sFLT1 and leads to pregnancy complications. J. Clin. Invest. 124, 4941–4952 (2014).
Anderson, E., Boese, Q., Khvorova, A. & Karpilow, J. Identifying siRNA-induced off-targets by microarray analysis. Methods Mol. Biol. 442, 45–63 (2008).
Osborn, M.F. et al. Guanabenz (Wytensin™) selectively enhances uptake and efficacy of hydrophobically modified siRNAs. Nucleic Acids Res. 43, 8664–8672 (2015).
Rajakumar, A. et al. Novel soluble Flt-1 isoforms in plasma and cultured placental explants from normotensive pregnant and preeclamptic women. Placenta 30, 25–34 (2009).
Coles, A.H. et al. A high-throughput method for direct detection of therapeutic oligonucleotide-induced gene silencing in vivo. Nucleic Acid Ther. 26, 86–92 (2016).
Nikan, M. et al. Docosahexaenoic acid conjugation enhances distribution and safety of siRNA upon local administration in mouse brain. Mol. Ther. Nucleic Acids 5, e344 (2016).
We thank D. Conte for help revising the manuscript and Khvorova Laboratory members for their support. This project was funded by the National Institutes of Health (R01 HD086111 and S10 OD020012) and the Bill and Melinda Gates Foundation (OPP1086170).
A.K. discloses ownership of stock in RXi Pharmaceuticals and Advirna. S.A.K. is a consultant to Thermofisher Scientific and owns stock in Aggamin Therapeutics. M.J.M. is employed by Moderna Therapeutics.
Integrated supplementary information
Total RNA was isolated from 6 normal (N) and 11 preeclamptic (PE) human placentas and analyzed by Polyadenylation Site sequencing (PAS-Seq). Data for computation were derived from (Ashar et al, 2017). All three sFLT1 mRNA isoforms are contributing to sFLT1 overexpression during PE.
Supplementary Figure 2 Specific hsiRNA-mediated downregulation of sFLT1 mRNA isoforms in human placental cytotrophoblast (CTB).
a) Dose-response curves of hsiRNAPPIB silencing of PPIB mRNA in CTB (n=3 biologically independent experiments, mean +SD). b) Dose-response curves of hsiRNAsFLT1-2283 and hsiRNAsFLT1-2519 silencing of sFLT1-i13 and sFLT1-e15a mRNAs in CTB (n=3 biologically independent experiments, mean + s.d.). hsiRNANTC – non-targeting hsiRNA control. ****P<0.0001, **P<0.01, *P<0.05, two-way ANOVA.
Supplementary Figure 3 Full chemical stabilization of cholesterol-conjugated hsiRNAsFLT1-2283 enables efficient placenta accumulation.
a) Representative images of placenta distribution (24 hours post treatment) of partially and fully modified Cy3-hsiRNAsFLT1-2283 (red) following 10 mg/kg IV or SC injections. Nuclei stained with DAPI (blue). Scale bar, 1mm. All images were acquired at identical settings (n=3 biologically independent animals). b) Guide strand quantification by PNA hybridization-based assay in placentas from a (n=6 biologically independent samples). Boxes represent 25 to 75 percentiles and whiskers indicate minimal and maximal values (****P<0.0001, **P=0.015, unpaired t test, two-tailed).
Supplementary Figure 4 Efficient silencing of sFLT1 mRNA in liver and kidney by hsiRNAsFLT1-2283 in pregnant mice.
Pregnant CD1 mice were injected at day E14 and E15 with 2X20 mg/kg of hsiRNAsFLT1 -2283 (IV, tail vein) and sacrificed at day E19. a) sFLT1-i13 mRNA levels were measured using QuantiGene® assay (Affymetrix), normalized to housekeeping gene, and presented as % of PBS control (n=6 biologically independent animals, mean + s.d., ****P<0.0001, one-way ANOVA). b) Amount of guide strand accumulated in mouse tissues measured by PNA hybridization assay (n=6 biologically independent samples, boxes represent 25 to 75 percentiles and whiskers indicate minimal and maximal values, ****P<0.0001, one-way ANOVA).
Pregnant CD1 mice were injected at day E14 and E15 with 2X20 mg/kg of hsiRNAsFLT1-2283, hsiRNANTC or PBS (IV, tail vein) and allowed to deliver pups on day E20. a-c). Newborn pups number and weights from mice injected with PBS or hsiRNAsFLT1 -2283 (n=9 biologically independent animals, boxes represent 25 to 75 percentiles and whiskers indicate minimal and maximal values, ns- non-significant, unpaired t test, two-tailed). d-e) Newborn pups number and weights from mice injected with PBS or hsiRNANTC (n=10 biologically independent animals, boxes represent 25 to 75 percentiles and whiskers indicate minimal and maximal values, ns- non-significant, unpaired t test, two-tailed).
Supplementary Figure 6 Efficient sFLT1 mRNA cleavage by hsiRNAsFLT1-2283 in mouse placenta (5′-RACE analysis).
Pregnant CD1 mice were injected at E14 and E15 with 2X20 mg/kg of hsiRNAsFLT1 -2283, hsiRNANTC or PBS (IV, tail vein) and sacrificed at E19. Total RNA was isolated from whole placenta and agarose gel of 5’-RACE PCR amplification with GR1 and GSP1 primers showed predicted cleavage product (~400 bp, indicated by Arrow). Representative image from two independent experiments. Corresponding sequencing result shown below.
Supplementary Figure 7 hsiRNAsFLT1-2283/2519 tissue concentrations after IV injection in pregnant mice.
Pregnant mice were injected with 2x20 mg/kg of hsiRNAsFLT1-2283/2519 at day E14 and E15 and tissues were collected at day E19. Milk was collected at post partum day P12. Guide strand concentration hsiRNAsFLT1-2283 and hsiRNAsFLT1-2519 were measured using PNA hybridization assay (n=2 biologically independent animals, mean +s.d.). # - milk samples concentrations are presented in ng/μl.
Supplementary Figure 8 Representative placental histology of mice treated with PBS, hsiRNA 2383 and 2283/2519 (2 × 20 mg/kg, IV, n = 4), showing anti-CD31 staining.
PBS treated placental labyrinth shows extensive staining for CD31 (upper panel), suggesting robust vascular network. Under higher magnifications (lower panel), PBS treated placental tissue displays small vessels filled with nucleated erythrocytes in close vicinity to maternal blood sinuses. There were no significant changes in the hsiRNA injected mice. D- decidua, Jz - junctional zone and L – labyrinth.
Pregnant baboons were injected with 20 mg/kg of hsiRNAsFLT1-2283/2519 around day 133 of gestation and newborns’ weights and centiles were recorded after delivery. ns- non-significant (n=9 biologically independent animals for control, n=3 for hsiRNA, P=0.1819, unpaired t test, two-tailed, boxes represent 25 to 75 percentiles and whiskers indicate minimal and maximal values). * - pregnancy was terminated before full term for unrelated conditions.
Supplementary Figure 10 hsiRNAsFLT1-2283/2519 blood, placenta and urine concentrations following a single IV injection in the baboon model of PE.
Pregnant baboons were injected with 20 mg/kg of hsiRNAsFLT1-2283/2519 around day 133 of gestation. Blood, urine and placenta biopsies were collected at the time points shows. Guide strand concentration hsiRNAsFLT1-2283 and hsiRNAsFLT1-2519 were measured using PNA hybridization assay (n=1).
About this article
Cite this article
Turanov, A., Lo, A., Hassler, M. et al. RNAi modulation of placental sFLT1 for the treatment of preeclampsia. Nat Biotechnol 36, 1164–1173 (2018). https://doi.org/10.1038/nbt.4297
An integrated model of preeclampsia: a multifaceted syndrome of the maternal cardiovascular-placental-fetal array
American Journal of Obstetrics and Gynecology (2021)
American Journal of Obstetrics and Gynecology (2021)
Human Reproduction Update (2021)
Biomarkers in Medicine (2021)
Docosanoic acid conjugation to siRNA enables functional and safe delivery to skeletal and cardiac muscles
Molecular Therapy (2021)